Intratio
Loading...
Skip to main content
Sign in Sign up
Model output · Signal date Oct. 16, 2026

Daily Signals

2758 companies scored · Total · absolute moveSwitch to Alpha · 30D 90D

Create a free account Unlock all ratings
Signal date 2026-10-16 Cut-offs from the 2026-10-16 run
Companies scored 2758 IC ≥ 0 · market cap ≥ $100M
Median forecast +2.43% Total · 90D
Long–short spread +6.50% Strong Buy minus Strong Sell, mean
Median IC 0.27 Spearman · 90D
Rating changes ▲ 167 ▼ 375 vs the previous run
Cross-section

Distribution of the day's forecasts

90D Total forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).

-1.8% 0 +7.9%
Signals · All

296 companies

Sorted by market cap ↓ · forecast rankings are part of the paid plans

# Ticker Sector IC Mkt cap Rating 30D 90D Δ
51 IONSIONIS PHARMACEUTICALS INC Life Sciences 0.39 $7.1B Unlock rating and forecasts
52 SYRESpyre Therapeutics, Inc. Life Sciences 0.16 $7.0B Unlock rating and forecasts
53 ALKSAlkermes plc. Life Sciences 0.44 $6.9B Unlock rating and forecasts
54 PRAXPraxis Precision Medicines, Inc. Life Sciences 0.41 $6.7B Unlock rating and forecasts
55 LNTHLantheus Holdings, Inc. Life Sciences 0.12 $6.5B Unlock rating and forecasts
56 IOVAIOVANCE BIOTHERAPEUTICS, INC. Life Sciences 0.40 $6.2B Unlock rating and forecasts
57 KNSAKiniksa Pharmaceuticals International, plc Life Sciences 0.00 $6.1B Unlock rating and forecasts
58 AMRXAmneal Pharmaceuticals, Inc. Life Sciences 0.48 $6.1B Neutral +1.02% +2.91% ·
59 RYTMRHYTHM PHARMACEUTICALS, INC. Life Sciences 0.23 $5.9B Unlock rating and forecasts
60 LGNDLIGAND PHARMACEUTICALS INC Life Sciences 0.02 $5.9B Unlock rating and forecasts
61 IMVTImmunovant, Inc. Life Sciences 0.28 $5.5B Unlock rating and forecasts
62 CGONCG Oncology, Inc. Life Sciences 0.27 $5.3B Unlock rating and forecasts
63 MIRMMirum Pharmaceuticals, Inc. Life Sciences 0.06 $5.2B Unlock rating and forecasts
64 COGTCogent Biosciences, Inc. Life Sciences 0.20 $5.1B Unlock rating and forecasts
65 PTCTPTC THERAPEUTICS, INC. Life Sciences 0.12 $4.9B Unlock rating and forecasts
66 SRRKScholar Rock Holding Corp Life Sciences 0.21 $4.9B Unlock rating and forecasts
67 ORKAOruka Therapeutics, Inc. Life Sciences 0.49 $4.8B Unlock rating and forecasts
68 CRSPCRISPR Therapeutics AG Life Sciences 0.30 $4.8B Unlock rating and forecasts
69 ERASErasca, Inc. Life Sciences 0.43 $4.7B Unlock rating and forecasts
70 MANEVeradermics, Inc Life Sciences 0.20 $4.5B Unlock rating and forecasts
71 TVTXTravere Therapeutics, Inc. Life Sciences 0.50 $4.4B Unlock rating and forecasts
72 DFTXDefinium Therapeutics, Inc. Life Sciences 0.21 $4.3B Unlock rating and forecasts
73 EWTXEdgewise Therapeutics, Inc. Life Sciences 0.23 $4.0B Unlock rating and forecasts
74 DNTHDianthus Therapeutics, Inc. /DE/ Life Sciences 0.39 $4.0B Unlock rating and forecasts
75 ADPTAdaptive Biotechnologies Corp Life Sciences 0.15 $3.8B Unlock rating and forecasts
76 INDVIndivior Pharmaceuticals, Inc. Life Sciences 0.52 $3.8B Unlock rating and forecasts
77 TNGXTango Therapeutics, Inc. Life Sciences 0.09 $3.7B Unlock rating and forecasts
78 ARQTArcutis Biotherapeutics, Inc. Life Sciences 0.31 $3.6B Unlock rating and forecasts
79 ABCLAbCellera Biologics Inc. Life Sciences 0.34 $3.6B Unlock rating and forecasts
80 OGNOrganon & Co. Life Sciences 0.45 $3.6B Unlock rating and forecasts
81 TLXTelix Pharmaceuticals Ltd Life Sciences 0.15 $3.6B Neutral +1.10% +3.17% ▼ 1
82 RLAYRelay Therapeutics, Inc. Life Sciences 0.43 $3.6B Unlock rating and forecasts
83 LEGNLegend Biotech Corp Life Sciences 0.03 $3.4B Unlock rating and forecasts
84 AMLXAmylyx Pharmaceuticals, Inc. Life Sciences 0.30 $3.3B Unlock rating and forecasts
85 ACADACADIA PHARMACEUTICALS INC Life Sciences 0.37 $3.3B Unlock rating and forecasts
86 XENEXenon Pharmaceuticals Inc. Life Sciences 0.46 $3.2B Unlock rating and forecasts
87 IDYAIDEAYA Biosciences, Inc. Life Sciences 0.30 $3.2B Unlock rating and forecasts
88 LQDALiquidia Corp Life Sciences 0.13 $3.1B Unlock rating and forecasts
89 RCUSArcus Biosciences, Inc. Life Sciences 0.19 $2.8B Unlock rating and forecasts
90 ELVNEnliven Therapeutics, Inc. Life Sciences 0.45 $2.7B Unlock rating and forecasts
91 ZLABZai Lab Ltd Life Sciences 0.51 $2.6B Unlock rating and forecasts
92 NEOGNEOGEN CORP Life Sciences 0.37 $2.6B Unlock rating and forecasts
93 NRIXNurix Therapeutics, Inc. Life Sciences 0.27 $2.5B Neutral +0.97% +3.01% ·
94 HCMHUTCHMED (China) Ltd Life Sciences 0.14 $2.5B Neutral +0.85% +2.62% ·
95 BEAMBeam Therapeutics Inc. Life Sciences 0.19 $2.4B Unlock rating and forecasts
96 ADMAADMA BIOLOGICS, INC. Life Sciences 0.26 $2.4B Unlock rating and forecasts
97 MBXMBX Biosciences, Inc. Life Sciences 0.05 $2.4B Unlock rating and forecasts
98 LIFEaTYR PHARMA INC Life Sciences 0.46 $2.4B Unlock rating and forecasts
99 PBHPrestige Consumer Healthcare Inc. Life Sciences 0.30 $2.4B Unlock rating and forecasts
100 BHCBausch Health Companies Inc. Life Sciences 0.51 $2.4B Neutral +0.84% +2.68% ·
51–100 of 296 Previous Next
Breadth

By sector

Median 90D forecast per sector. Click to filter.

Finance or Crypto Assets48 +4.8% Life Sciences296 +4.5% Technology381 +3.1% Manufacturing434 +2.4% Trade & Services356 +2.2% Industrial Applications and Services290 +2.2% Energy & Transportation313 +2.1% Finance395 +2.0% Real Estate & Construction233 +1.8% Crypto Assets12 -0.1%
Since the previous run

Rating changes

▲ 167▼ 375
Which companies were upgraded or downgraded is part of the paid plans.
Next step

Unlock the full ranking

Every company's rating, its 30- and 90-day forecasts, the forecast and IC-weighted rankings, the daily rating changes and CSV export.

See plans Create a free account
Methodology

Ratings are relative: the forecasts of the latest complete daily run (2026-10-16) are ranked and cut at the 15th, 35th, 65th and 85th percentiles, so Strong Sell is the bottom 15%, Sell the next 20%, Neutral the middle 30%, Buy the next 20% and Strong Buy the top 15%. Expected absolute price move over the horizon, market included. This is the number a price target is built from. IC is the company's Spearman information coefficient between its past forecasts and the realised returns at the selected horizon; IC-weighted ranking multiplies each forecast by its IC (negative IC counts as zero). Δ is the rating move since the company's previous signal, in rating steps. Each company shows its latest signal, including one from a run still in progress; every signal is rated against the cut-offs above. Quantitative research output, not investment advice.

Intratio is a quantitative research firm specializing in systematic equity forecasting and portfolio optimization. We serve institutional investors, hedge funds, and family offices worldwide.

Quantitative research output, not investment advice.

Connect
English
Français
Español
العربية
简体中文
Deutsch
日本語
한국어
Português
Русский
Türkçe
हिन्दी
Bahasa Indonesia
Italiano

2018–2026 © Intratio. All Rights Reserved.

  • Visa
  • Mastercard
  • American Express
  • PayPal